Differential effect on mortality of the timing of initiation of renal replacement therapy according to the criteria used to diagnose acute kidney injury: an IDEAL-ICU substudy.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
17 08 2023
Historique:
received: 01 06 2023
accepted: 05 08 2023
medline: 21 8 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: epublish

Résumé

This substudy of the randomized IDEAL-ICU trial assessed whether the timing of renal replacement therapy (RRT) initiation has a differential effect on 90-day mortality, according to the criteria used to diagnose acute kidney injury (AKI), in patients with early-stage septic shock. Three groups were considered according to the criterion defining AKI: creatinine elevation only (group 1), reduced urinary output only (group 2), creatinine elevation plus reduced urinary output (group 3). Primary outcome was 90-day all-cause death. Secondary endpoints were RRT-free days, RRT dependence and renal function at discharge. We assessed the interaction between RRT strategy (early vs. delayed) and group, and the association between RRT strategy and mortality in each group by logistic regression. Of 488 patients enrolled, 205 (42%) patients were in group 1, 174 (35%) in group 2, and 100 (20%) in group 3. The effect of RRT initiation strategy on 90-day mortality across groups showed significant heterogeneity (adjusted interaction p = 0.021). Mortality was 58% vs. 42% for early vs. late RRT initiation, respectively, in group 1 (p = 0.028); 57% vs. 67%, respectively, in group 2 (p = 0.18); and 58% vs. 55%, respectively, in group 3 (p = 0.79). There was no significant difference in secondary outcomes. The timing of RRT initiation has a differential impact on outcome according to AKI diagnostic criteria. In patients with elevated creatinine only, early RRT initiation was associated with significantly increased mortality. In patients with reduced urine output only, late RRT initiation was associated with a nonsignificant, 10% absolute increase in mortality.

Sections du résumé

BACKGROUND
This substudy of the randomized IDEAL-ICU trial assessed whether the timing of renal replacement therapy (RRT) initiation has a differential effect on 90-day mortality, according to the criteria used to diagnose acute kidney injury (AKI), in patients with early-stage septic shock.
METHODS
Three groups were considered according to the criterion defining AKI: creatinine elevation only (group 1), reduced urinary output only (group 2), creatinine elevation plus reduced urinary output (group 3). Primary outcome was 90-day all-cause death. Secondary endpoints were RRT-free days, RRT dependence and renal function at discharge. We assessed the interaction between RRT strategy (early vs. delayed) and group, and the association between RRT strategy and mortality in each group by logistic regression.
RESULTS
Of 488 patients enrolled, 205 (42%) patients were in group 1, 174 (35%) in group 2, and 100 (20%) in group 3. The effect of RRT initiation strategy on 90-day mortality across groups showed significant heterogeneity (adjusted interaction p = 0.021). Mortality was 58% vs. 42% for early vs. late RRT initiation, respectively, in group 1 (p = 0.028); 57% vs. 67%, respectively, in group 2 (p = 0.18); and 58% vs. 55%, respectively, in group 3 (p = 0.79). There was no significant difference in secondary outcomes.
CONCLUSION
The timing of RRT initiation has a differential impact on outcome according to AKI diagnostic criteria. In patients with elevated creatinine only, early RRT initiation was associated with significantly increased mortality. In patients with reduced urine output only, late RRT initiation was associated with a nonsignificant, 10% absolute increase in mortality.

Identifiants

pubmed: 37592355
doi: 10.1186/s13054-023-04602-7
pii: 10.1186/s13054-023-04602-7
pmc: PMC10436583
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

316

Subventions

Organisme : Ministère des Affaires Sociales et de la Santé
ID : PHRC 2011/A00519-34
Organisme : Ministère des Affaires Sociales et de la Santé
ID : PHRC 2011/A00519-34
Organisme : Ministère des Affaires Sociales et de la Santé
ID : PHRC 2011/A00519-34

Investigateurs

Raphaël Clere-Jehl (R)
Romain Hernu (R)
Florent Montini (F)
Rémi Bruyère (R)
Christine Lebert (C)
Julien Bohé (J)
Julio Badie (J)
Jean-Pierre Eraldi (JP)
Jean-Philippe Rigaud (JP)
Bruno Levy (B)
Shidasp Siami (S)
Guillaume Louis (G)
Lila Bouadma (L)
Jean-Michel Constantin (JM)
Emmanuelle Mercier (E)
Kada Klouche (K)
Damien Du Cheyron (D)
Gaël Piton (G)
Djillali Annane (D)
Samir Jaber (S)
Therry van der Linden (T)
Gilles Blasco (G)
Jean-Paul Mira (JP)
Carole Schwebel (C)
Loïc Chimot (L)
Philippe Guiot (P)
Mai-Anh Nay (MA)
Ferhat Meziani (F)
Julie Helms (J)
Claire Roger (C)
Benjamin Louart (B)

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Trials. 2014 Jul 07;15:270
pubmed: 24998258
N Engl J Med. 2016 Jul 14;375(2):122-33
pubmed: 27181456
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
pubmed: 23744003
Am J Kidney Dis. 2022 Mar;79(3):417-426
pubmed: 34461167
Crit Care. 2007;11(6):232
pubmed: 18001499
Nephrol Dial Transplant. 2012 Mar;27(3):947-52
pubmed: 21908413
Crit Care. 2022 Mar 21;26(1):64
pubmed: 35313942
J Crit Care. 2009 Mar;24(1):129-40
pubmed: 19272549
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1015-23
pubmed: 24742481
J Am Soc Nephrol. 2015 Aug;26(8):2023-31
pubmed: 25655065
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
N Engl J Med. 2018 Oct 11;379(15):1431-1442
pubmed: 30304656
JAMA. 2016 May 24-31;315(20):2190-9
pubmed: 27209269
Rev Bras Ter Intensiva. 2013 Oct-Dec;25(4):290-6
pubmed: 24553510
Crit Care Med. 2008 Jan;36(1):296-327
pubmed: 18158437
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219

Auteurs

Saber Davide Barbar (SD)

Unité de Réanimation Médicale, Service des Réanimations, Centre Hospitalier Universitaire de Nîmes, Hôpital Caremeau, Place du Prof Robert Debré, 30029, Nîmes, France. saber.barbar@chu-nimes.fr.
Université de Montpellier, Montpellier, France. saber.barbar@chu-nimes.fr.

Abderrahmane Bourredjem (A)

CIC 1432, Epidémiologie Clinique, Centre Hospitalier Universitaire Dijon-Bourgogne, BP 1541, Dijon, France.

Rémi Trusson (R)

Unité de Réanimation Médicale, Service des Réanimations, Centre Hospitalier Universitaire de Nîmes, Hôpital Caremeau, Place du Prof Robert Debré, 30029, Nîmes, France.

Auguste Dargent (A)

Medical Intensive Care Unit, Hospices Civils de Lyon, Hôpital Lyon-Sud, 69437, Lyon, France.

Christine Binquet (C)

CIC 1432, Epidémiologie Clinique, Centre Hospitalier Universitaire Dijon-Bourgogne, BP 1541, Dijon, France.

Jean-Pierre Quenot (JP)

CIC 1432, Epidémiologie Clinique, Centre Hospitalier Universitaire Dijon-Bourgogne, BP 1541, Dijon, France.
Service de Médecine Intensive Réanimation, CHU Dijon, Dijon, France.
Lipness Team, INSERM Research Center LNC-UMR1231 and LabExLipSTIC, Université de Bourgogne, Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH